Ibio Stock Price, News & Analysis

iBio (Nasdaq: IBIO) has announced the pricing of a $50 million public offering of pre-funded warrants and accompanying Series G warrants. The offering includes 71,540,000 pre-funded warrants to purchase common stock and Series G warrants to purchase 35,770,000 shares, along with Series H warrants.

The combined offering price is set at $0.699 per unit, with Series G and H warrants having an exercise price of $0.70 per share. If all warrants are exercised, iBio could receive additional gross proceeds of approximately $50 million. The company plans to use the proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and fund working capital requirements.

[ "Potential total gross proceeds of up to $100 million if all warrants are exercised", "Funds will advance key preclinical cardiometabolic programs IBIO-610 and IBIO-600", "Multiple tier-1 investment banks involved in the offering including Leerink Partners as lead bookrunner" ]

iBio (Nasdaq: IBIO), an AI-driven precision antibody therapies company, has announced a proposed underwritten public offering. The offering includes pre-funded warrants to purchase common stock and accompanying Series G and Series H warrants.

The company plans to use the proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 (myostatin and activin A bispecific) and IBIO-600 programs, as well as other preclinical pipeline assets. Leerink Partners is leading the offering as the lead bookrunning manager, with LifeSci Capital and Oppenheimer & Co. serving as additional bookrunning managers.

iBio (NASDAQ:IBIO) has announced promising preclinical results for its novel amylin receptor agonist antibody in obesity treatment. The engineered antibody demonstrated a significant 60% reduction in acute food intake in mouse models, comparable to the 67% reduction achieved by a clinically advanced DACRA peptide.

This marks the third target from iBio's partnership with AstralBio, leveraging their AI-enabled antibody discovery platform to develop selective amylin receptor targeting treatments. The approach shows potential for both monotherapy and combination therapy with GLP-1 receptor agonists, with current amylin analogs achieving up to 22.7% weight loss in combination with semaglutide and 11.8% as monotherapy in clinical development.

iBio (NASDAQ:IBIO) has announced a conference call scheduled for June 24, 2025, at 8:30 a.m. ET to discuss its obesity and cardiometabolic disease pipeline. CEO and CSO Martin Brenner will present updates on the company's next-generation antibody medicines, including IBIO-600, their long-acting Myostatin treatment, and new preclinical data on Activin E.

The presentation will also reveal a third target in their AstralBio Collaboration. The company aims to develop targeted, longer-lasting therapies with improved tolerability and sustainable efficacy. Investors can access the webcast through iBio's website, with a replay available for approximately 60 days.

iBio has initiated a non-human primate (NHP) study for IBIO-610, its first-in-class Activin E antibody candidate, following promising preclinical results. The study will evaluate pharmacokinetics and efficacy in obese, elderly NHPs, with initial data expected in early Q4. Preclinical data showed IBIO-610 achieved 8.9% body weight loss alone and demonstrated significant fat reduction capabilities: 26% overall fat reduction and 31% subcutaneous fat reduction. When combined with GLP-1 therapy, these numbers increased to 77% and 74% respectively. Notably, IBIO-610 prevented weight regain after GLP-1 treatment discontinuation in diet-induced obese mice. These findings will be presented at the American Diabetes Association's 85th Scientific Sessions on June 23rd in Chicago.

iBio (NASDAQ: IBIO) has announced promising preclinical results for its first-in-class Activin E antibody in treating obesity. In a 4-week study with obese mice, the antibody achieved a 26% reduction in fat mass while preserving muscle mass. The treatment demonstrated significant reductions in various fat deposits: 31% in subcutaneous fat and 34-37% in visceral fat depots linked to cardiometabolic disease risk.

When combined with a GLP-1 receptor agonist, the Activin E antibody showed remarkable synergy, achieving a 77% reduction in total fat mass and total weight loss of 35.3% - surpassing GLP-1 alone by 7.5%. Unlike current obesity drugs that may reduce muscle mass, iBio's approach focuses on fat-specific weight loss, potentially offering a more effective solution for obesity treatment while maintaining physical function and healthy metabolism.

iBio (IBIO) reported its fiscal Q3 2025 financial results and corporate updates. The company reported a net loss of $4.9 million ($0.49 per share) compared to $2.6 million ($0.71 per share) in Q3 2024. R&D expenses increased to $1.9 million from $0.9 million, while G&A expenses rose to $3.0 million from $2.7 million.

Key developments include: uplisting to Nasdaq, promising non-human primate data for IBIO-600 (anti-myostatin antibody), in-licensing of a first-in-class Activin E antibody from AstralBio, and raising $6.2 million through warrant inducement. Cash position stood at $5.2 million as of March 31, 2025, increasing to $10.5 million by May 1, 2025 post-warrant transaction.

iBio, an AI-driven innovator of precision antibody therapies, has secured $6.2 million through a warrant inducement transaction with institutional investors. The deal involves existing warrant holders agreeing to purchase 5,626,685 shares of common stock at a reduced price of $1.11 per share.

As part of the agreement, investors received new warrants to purchase up to 11,253,370 shares at $0.86 per share, with a five-year expiration period. The transaction is expected to close around April 30, 2025, with Chardan serving as the exclusive financial advisor.

The company plans to use the net proceeds for working capital and general corporate purposes. The new securities are being offered through a private placement and will require registration with the SEC before they can be sold in the United States.

iBio (NASDAQ: IBIO) has announced a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, discovered using iBio's Machine-Learning Antibody Engine. The antibody shows promise in inducing fat-selective weight loss and protecting against obesity and cardiometabolic disease.

Preclinical studies demonstrated strong antibody binding, inhibition of Activin E signaling, and fat-specific weight loss in an obese rodent model. The antibody represents the first functional inhibitor of Activin E, a genetically validated therapeutic target important for energy balance and fat distribution regulation.

Under the agreement terms, AstralBio provided iBio a $750,000 credit toward the option fee and will be eligible for development and commercialization milestone payments up to $28 million, plus low to mid-single-digit sublicense fees. Additionally, iBio amended its collaboration with AstralBio to add a fifth target for cardiometabolic disease treatment.